European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's ...

As one study finds, traditional titles are leading enterprise Gen AI adoption and the Chief AI Officer role continues to grow ...

The change in leadership comes shortly after Indivior warned that it is expecting a sharp decline in its revenues in 2025, ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

Operator Good afternoon, and welcome to AbCellera's full-year 2024 business update conference call. My name is Tamia, and I will facilitate the audio portion of today's interactive broadcast.

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and ...

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Con ...